Pivotal role of DPYSL2A in KLF4-mediated monocytic differentiation of acute myeloid leukemia cells.

Scientific Reports
Mina NouraSouichi Adachi

Abstract

Although the biological importance of Krüppel-like factor 4 (KLF4) transcription factor in the terminal differentiation of hematopoietic cells to the monocytes has been well established, the underlying mechanisms remain elusive. To clarify the molecular basis of KLF4-mediated monocytic differentiation, we performed detailed genetic studies in acute myeloid leukemia (AML) cells. Here, we report that dihydropyrimidinase like 2 (DPYSL2), also known as CRMP2, is a novel key differentiation mediator downstream of KLF4 in AML cells. Interestingly, we discovered that KLF4-mediated monocytic differentiation is selectively dependent on one specific isoform, DPYSL2A, but not on other DPYSL family genes. Terminal differentiation to the monocytes and proliferation arrest in AML cells induced by genetic or pharmacological upregulation of KLF4 were significantly reversed by short hairpin RNA (shRNA)-mediated selective depletion of DPYSL2A. Chromatin immunoprecipitation assay revealed that KLF4 associates with the proximal gene promoter of DPYSL2A and directly transactivates its expression. Together with the unique expression patterns of KLF4 and DPYSL2 limited to the differentiated monocytes in the hematopoietic system both in human and mous...Continue Reading

References

Jul 10, 2001·The Journal of Biological Chemistry·J J Bieker
Feb 16, 2002·Methods : a Companion to Methods in Enzymology·K J Livak, T D Schmittgen
Jul 23, 2002·Nature Cell Biology·Yuko FukataKozo Kaibuchi
Oct 4, 2005·Proceedings of the National Academy of Sciences of the United States of America·Aravind SubramanianJill P Mesirov
Jul 31, 2007·International Journal of Toxicology·Gunjan GoelKlaus Becker
Sep 1, 2007·The EMBO Journal·Mark W FeinbergMukesh K Jain
Feb 12, 2008·Nature Cell Biology·Jianming JiangHuck-Hui Ng
Aug 8, 2009·Journal of Neurochemistry·Nariko ArimuraKozo Kaibuchi
Sep 8, 2012·Journal of Alzheimer's Disease : JAD·Patrícia Natalia SilvaMarília Cardoso Smith
Dec 4, 2012·The Journal of Clinical Investigation·Katrin FaberStefan Fröhling
Sep 17, 2015·The New England Journal of Medicine·Hartmut DöhnerClara D Bloomfield
Feb 27, 2017·Gene·Amr M Ghaleb, Vincent W Yang
Feb 28, 2017·JCI Insight·Panjamaporn SangwungMukesh K Jain
May 23, 2017·The Journal of Clinical Investigation·Ken MoritaYasuhiko Kamikubo
Dec 2, 2017·Nature Reviews. Cancer·Hugues de Thé
May 29, 2018·Cell Stem Cell·Christian BaumgartnerManuela Baccarini
Nov 14, 2018·Journal of Oncology Practice·Afaf E G OsmanRichard A Larson

❮ Previous
Next ❯

Datasets Mentioned

BETA
GSE22845
GSE37642
GSE21261
GSE101751

Methods Mentioned

BETA
ChIP
flow cytometry
PMA
immunoprecipitation
PCR

Software Mentioned

FlowJo
Image Lab
Gene set enrichment analysis ( GSEA )
Affymetrix
Microarray Suite

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.